Cullinan Therapeutics (CGEM), Taiho Pharmaceutical and Taiho Oncology said late Tuesday a phase 1/2 clinical trial of zipalertinib monotherapy in certain patients with non-small cell lung cancer met its primary endpoint of overall response rate.
These results are based on the phase 2b part of the study, and the companies plan to submit for US regulatory approval in the second half of 2025, they said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.